---
schema_version: "secwatch.filing_event.v1"
accession: "0001789769-22-000090"
form_type: "8-K"
ticker: "TIL"
cik: "0001789769"
company_name: "Instil Bio, Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T04:17:42.330068+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Instil Bio presents CoStAR platform data at SITC; ITIL-306 Phase 1 ongoing

## Summary
- Pre-clinical data showed CoStAR amplified T-cell responses across all FRα expression levels, supporting clinical exploration in multiple solid tumors.
- First patient dosed in ITIL-306 Phase 1 study in October 2022; evaluating safety and feasibility in advanced solid tumors.
- Treatment regimen is free of high-dose interleukin-2.
- Posters presented at SITC 2022; available on company website.

## SEC filing metadata
- accession: 0001789769-22-000090
- form_type: 8-K
- ticker: TIL
- cik: 0001789769
- company_name: Instil Bio, Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789769/000178976922000090/0001789769-22-000090-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789769/000178976922000090/til-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001789769-22-000090
- JSON: https://secwatch.observer/filing/0001789769-22-000090.json
- Plain text: https://secwatch.observer/filing/0001789769-22-000090.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.